We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
quick look coverage of GLP-1 drugs.
- Abstract
A survey conducted by the International Foundation of Employee Benefit Plans in January 2024 focused on Canadian employers' coverage and considerations for glucagon-like peptide-1 (GLP-1) drugs. These medications are traditionally used for diabetes treatment but are increasingly sought for weight loss, despite lacking approval from Health Canada for this indication. Of the organizations surveyed, 66% provided coverage for GLP-1 drugs for diabetes, 17% covered them for both diabetes and weight loss, and 1% covered them solely for weight loss. Some organizations that covered GLP-1 drugs only for diabetes are considering extending coverage to include weight loss. The survey also explored factors considered when deciding on GLP-1 coverage for obesity care and cost-control mechanisms in place for GLP-1 drugs for weight loss. The article provides data on services covered under extended health plans for diabetes or weight loss. However, caution should be exercised when generalizing the findings due to the small number of respondents.
- Subjects
INTERNATIONAL Foundation of Employee Benefit Plans; EMPLOYEE benefits; DRUGS; NUTRITION counseling
- Publication
Plans & Trusts, 2024, Vol 42, Issue 2, p6
- ISSN
2164-3857
- Publication type
Article